Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)	3 Months Ended
	Mar. 31, 2026	Mar. 31, 2025
Operating expenses:
Research and development expenses	$ 3,457,032	$ 5,830,999
General and administrative expenses	3,064,055	3,274,759
Total operating expenses	6,521,087	9,105,758
Loss from operations	(6,521,087)	(9,105,758)
Interest income (expenses), net
Interest income	186,814	377,849
Interest expense	(1,014,783)	(930,878)
Interest income (expenses), net	(827,969)	(553,029)
Loss before income taxes	(7,349,056)	(9,658,787)
Benefit for income taxes	0	1,169,820
Net loss	(7,349,056)	(8,488,967)
Comprehensive loss	$ (7,349,056)	$ (8,488,967)
Per share information:
Net loss per share, basic (in dollars per share)	$ (0.13)	$ (0.21)
Net loss per share, diluted (in dollars per share)	$ (0.13)	$ (0.21)
Weighted average common shares outstanding, basic (in shares)	55,496,279	40,521,001
Weighted average common shares outstanding, diluted (in shares)	55,496,279	40,521,001